Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
Minimal residual disease (MRD), both before and after transplantation, is a clinically important yet relatively poorly defined aspect of allogeneic hematopoietic stem cell transplantation (alloHSCT). The clinical relevance of MRD in the context of alloHSCT has been demonstrated by its association with the development of clinical relapse. However, with the possible exception of chronic myeloid leukemia (CML), the specific techniques, timing, frequency, and clinical utility, relative to improvement in patient outcomes, for monitoring MRD in the setting of alloHSCT has yet to be clearly defined. A concise overview of monitoring techniques for detecting MRD, as well as treatment strategies and biological and clinical research initiatives for MRD suggested by the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, is covered in this article.
University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Nicolaus
N
Kröger
Koichi
K
Miyamura
Michael R
MR
Bishop
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000628:therapy; D018365:Neoplasm, Residual / Q000175:diagnosis*; D012008:Recurrence; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents